COSCIENS Biopharma annual capital expenditures (capex)
2015
2016
2017
2018
2021
2022
2023
2024
2025
COSCIENS Biopharma Capital Expenditures (CapEx) Growth & History (CSCIF)
COSCIENS Biopharma's capital expenditures (capex) was $706,000 for fiscal 2025.
View full COSCIENS Biopharma company overviewCOSCIENS Biopharma annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $706,000 | −$455,000 | −39.19% |
| 2024 | 2024-12-31 | $1.2M | $439,000 | +60.80% |
| 2023 | 2023-12-31 | $722,000 | $418,000 | +137.50% |
| 2022 | 2022-12-31 | $304,000 | $274,000 | +913.33% |
| 2021 | 2021-12-31 | $30,000 | — | — |
| 2018 | 2018-12-31 | $9,000 | $5,000 | +125.00% |
| 2017 | 2017-12-31 | $4,000 | −$62,000 | −93.94% |
| 2016 | 2016-12-31 | $66,000 | $40,000 | +153.85% |
| 2015 | 2015-12-31 | $26,000 | — | — |
COSCIENS Biopharma quarterly capital expenditures (capex)
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $208,000 | $159,000 | +324.49% |
| Q1 2026 | 2026-03-31 | $2,000 | −$613,000 | −99.67% |
| Q4 2025 | 2025-12-31 | $38,000 | −$271,000 | −87.70% |
| Q3 2025 | 2025-09-30 | $4,000 | −$127,000 | −96.95% |
| Q2 2025 | 2025-06-30 | $49,000 | −$108,000 | −68.79% |
| Q1 2025 | 2025-03-31 | $615,000 | $51,000 | +9.04% |
| Q4 2024 | 2024-12-31 | $309,000 | −$307,000 | −49.84% |
| Q3 2024 | 2024-09-30 | $131,000 | $81,000 | +162.00% |
| Q2 2024 | 2024-06-30 | $157,000 | $103,000 | +190.74% |
| Q1 2024 | 2024-03-31 | $564,000 | $562,000 | +28100.00% |
| Q4 2023 | 2023-12-31 | $616,000 | $369,000 | +149.39% |
| Q3 2023 | 2023-09-30 | $50,000 | $41,000 | +455.56% |
| Q2 2023 | 2023-06-30 | $54,000 | $12,000 | +28.57% |
| Q1 2023 | 2023-03-31 | $2,000 | −$4,000 | −66.67% |
| Q4 2022 | 2022-12-31 | $247,000 | $242,000 | +4840.00% |
| Q3 2022 | 2022-09-30 | $9,000 | $4,000 | +80.00% |
| Q2 2022 | 2022-06-30 | $42,000 | $39,000 | +1300.00% |
| Q1 2022 | 2022-03-31 | $6,000 | −$11,000 | −64.71% |
| Q4 2021 | 2021-12-31 | $5,000 | — | — |
| Q3 2021 | 2021-09-30 | $5,000 | — | — |
| Q2 2021 | 2021-06-30 | $3,000 | — | — |
| Q1 2021 | 2021-03-31 | $17,000 | — | — |
COSCIENS Biopharma capital expenditures (capex) trends
Between the periods ended 2015-12-31 and 2025-12-31, COSCIENS Biopharma's capital expenditures (capex) increased from $26,000 to $706,000, a change of $680,000. The latest reported quarter, Q2 2026, shows $208,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review COSCIENS Biopharma source filings ↗